Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 672829, 10 pages
http://dx.doi.org/10.1155/2008/672829
Review Article

The Role of the PAX8/PPAR Fusion Oncogene in Thyroid Cancer

1Division of Endocrinology, Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USA
2Department of Laboratory Medicine and Pathology, Mayo Clinic & Foundation, Rochester, MN 55905, USA
3Department of Biochemistry and Molecular Biology, Mayo Clinic & Foundation, Rochester, MN 55905, USA

Received 30 July 2008; Accepted 9 September 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Kimberly A. Placzkowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts and Figures 2008, American Cancer Society, Atlanta, Ga, USA, 2008.
  2. J. Auwerx, “PPARγ, the ultimate thrifty gene,” Diabetologia, vol. 42, no. 9, pp. 1033–1049, 1999. View at Publisher · View at Google Scholar
  3. T. G. Kroll, P. Sarraf, L. Pecciarini et al., “PAX8-PPAR?1 fusion oncogene in human thyroid carcinoma,” Science, vol. 289, no. 5483, pp. 1357–1360, 2000. View at Publisher · View at Google Scholar
  4. S. K. G. Grebe, B. McIver, I. D. Hay et al., “Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 11, pp. 3684–3691, 1997. View at Publisher · View at Google Scholar
  5. M. A. Herrmann, I. D. Hay, D. H. Bartelt Jr. et al., “Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers,” The Journal of Clinical Investigation, vol. 88, no. 5, pp. 1596–1604, 1991. View at Publisher · View at Google Scholar
  6. R. B. Jenkins, I. D. Hay, J. F. Herath et al., “Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma,” Cancer, vol. 66, no. 6, pp. 1213–1220, 1990. View at Publisher · View at Google Scholar
  7. C. A. French, E. K. Alexander, E. S. Cibas et al., “Genetic and biological subgroups of low-stage follicular thyroid cancer,” The American Journal of Pathology, vol. 162, no. 4, pp. 1053–1060, 2003. View at Google Scholar
  8. J. Mark, C. Ekedahl, R. Dahlenfors, and B. Westermark, “Cytogenetical observations in five human anaplastic thyroid carcinomas,” Hereditas, vol. 107, no. 2, pp. 163–174, 1987. View at Publisher · View at Google Scholar
  9. W.-O. Lui, S. Kytölä, L. Ånfalk, C. Larsson, and L.-O. Farnebo, “Balanced translocation (3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma?” Cancer Genetics and Cytogenetics, vol. 119, no. 2, pp. 109–112, 2000. View at Publisher · View at Google Scholar
  10. G. Sozzi, M. Miozzo, T. C. Cariani et al., “A t(2;3)(q12-13;p24-25) in follicular thyroid adenomas,” Cancer Genetics and Cytogenetics, vol. 64, no. 1, pp. 38–41, 1992. View at Publisher · View at Google Scholar
  11. L. Roque, S. Castedo, A. Clode, and J. Soares, “Deletion of 3p25pter in a primary follicular thyroid carcinoma and its metastasis,” Genes, Chromosomes & Cancer, vol. 8, no. 3, pp. 199–203, 1993. View at Publisher · View at Google Scholar
  12. A. Aiello, G. Pandini, F. Frasca et al., “Peroxisomal proliferator-activated receptor-? agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006. View at Publisher · View at Google Scholar
  13. N. Hayashi, S. Nakamori, N. Hiraoka et al., “Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma,” International Journal of Oncology, vol. 24, no. 1, pp. 89–95, 2004. View at Google Scholar
  14. M. L. Martelli, R. Iuliano, I. Le Pera et al., “Inhibitory effects of peroxisome proliferator-activated receptor ? on thyroid carcinoma cell growth,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 10, pp. 4728–4735, 2002. View at Publisher · View at Google Scholar
  15. K. Ohta, T. Endo, and T. Onaya, “The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues,” Biochemical & Biophysical Research Communications, vol. 174, no. 3, pp. 1148–1153, 1991. View at Publisher · View at Google Scholar
  16. J.-W. Park, R. Zarnegar, H. Kanauchi et al., “Troglitazone, the peroxisome proliferator-activated receptor-? agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines,” Thyroid, vol. 15, no. 3, pp. 222–231, 2005. View at Publisher · View at Google Scholar
  17. Y. Chen, S.-M. Wang, J.-C. Wu, and S.-H. Huang, “Effects of PPARγ agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line,” Journal of Cellular Biochemistry, vol. 98, no. 4, pp. 1021–1035, 2006. View at Publisher · View at Google Scholar
  18. S. Kitamura, Y. Miyazaki, Y. Shinomura, S. Kondo, S. Kanayama, and Y. Matsuzawa, “Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells,” Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 75–80, 1999. View at Google Scholar
  19. J. A. Keelan, T. A. Sato, K. W. Marvin, J. Lander, R. S. Gilmour, and M. D. Mitchell, “15-deoxy-Δ12,14-prostaglandin J2 a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells,” Biochemical and Biophysical Research Communications, vol. 262, no. 3, pp. 579–585, 1999. View at Publisher · View at Google Scholar
  20. N. Takahashi, T. Okumura, W. Motomura, Y. Fujimoto, I. Kawabata, and Y. Kohgo, “Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells,” FEBS Letters, vol. 455, no. 1-2, pp. 135–139, 1999. View at Publisher · View at Google Scholar
  21. P. Tontonoz, S. Singer, B. M. Forman et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor ? and the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997. View at Publisher · View at Google Scholar
  22. T. Kubota, K. Koshizuka, E. A. Williamson et al., “Ligand for peroxisome proliferator-activated receptor ? (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,” Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998. View at Google Scholar
  23. E. Elstner, C. Müller, K. Koshizuka et al., “Ligands for peroxisome proliferator-activated receptor? and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998. View at Publisher · View at Google Scholar
  24. R. E. Weiss and S. Refetoff, “Resistance to thyroid hormone,” Reviews in Endocrine & Metabolic Disorders, vol. 1, no. 1-2, pp. 97–108, 2000. View at Publisher · View at Google Scholar
  25. H. Suzuki, M. C. Willingham, and S.-Y. Cheng, “Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis,” Thyroid, vol. 12, no. 11, pp. 963–969, 2002. View at Publisher · View at Google Scholar
  26. H. Ying, H. Suzuki, H. Furumoto et al., “Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma,” Carcinogenesis, vol. 24, no. 9, pp. 1467–1479, 2003. View at Publisher · View at Google Scholar
  27. H. Ying, H. Suzuki, L. Zhao, M. C. Willingham, P. Meltzer, and S.-Y. Cheng, “Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis,” Cancer Research, vol. 63, no. 17, pp. 5274–5280, 2003. View at Google Scholar
  28. A. R. Marques, C. Espadinha, M. J. Frias et al., “Underexpression of peroxisome proliferator-activated receptor (PPAR)? in PAX8/PPAR?-negative thyroid tumours,” British Journal of Cancer, vol. 91, no. 4, pp. 732–738, 2004. View at Publisher · View at Google Scholar
  29. M. A. Aldred, C. Morrison, O. Gimm et al., “Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas,” Oncogene, vol. 22, no. 22, pp. 3412–3416, 2003. View at Publisher · View at Google Scholar
  30. T. E. Akiyama, C. J. Nicol, and F. J. Gonzalez, “On par with PPARs,” Trends in Genetics, vol. 17, no. 6, pp. 310–312, 2001. View at Publisher · View at Google Scholar
  31. G. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPAR?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002. View at Publisher · View at Google Scholar
  32. Y. Kato, H. Ying, L. Zhao et al., “PPAR? insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-?B signaling pathway,” Oncogene, vol. 25, no. 19, pp. 2736–2747, 2006. View at Publisher · View at Google Scholar
  33. K. Setoguchi, Y. Misaki, Y. Terauchi et al., “Peroxisome proliferator-activated receptor-? haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis,” The Journal of Clinical Investigation, vol. 108, no. 11, pp. 1667–1675, 2001. View at Publisher · View at Google Scholar
  34. M. L. C. Khoo, N. J. P. Beasley, S. Ezzat, J. L. Freeman, and S. L. Asa, “Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 4, pp. 1814–1818, 2002. View at Publisher · View at Google Scholar
  35. J. Suh and A. B. Rabson, “NF-κB activation in human prostate cancer: important mediator or epiphenomenon?” Journal of Cellular Biochemistry, vol. 91, no. 1, pp. 100–117, 2004. View at Publisher · View at Google Scholar
  36. A. R. Marques, C. Espadinha, A. L. Catarino et al., “Expression of PAX8-PPAR?1 rearrangements in both follicular thyroid carcinomas and adenomas,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 8, pp. 3947–3952, 2002. View at Publisher · View at Google Scholar
  37. L. Cheung, M. Messina, A. Gill et al., “Detection of the PAX8-PPAR? fusion oncogene in both follicular thyroid carcinomas and adenomas,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 354–357, 2003. View at Publisher · View at Google Scholar
  38. Z. Zhu, M. Gandhi, M. N. Nikiforova, A. H. Fischer, and Y. E. Nikiforov, “Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations,” American Journal of Clinical Pathology, vol. 120, no. 1, pp. 71–77, 2003. View at Publisher · View at Google Scholar
  39. M. N. Nikiforova, P. W. Biddinger, C. M. Caudill, T. G. Kroll, and Y. E. Nikiforov, “PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses,” American Journal of Surgical Pathology, vol. 26, no. 8, pp. 1016–1023, 2002. View at Publisher · View at Google Scholar
  40. L. Lacroix, C. Mian, T. Barrier et al., “PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues,” European Journal of Endocrinology, vol. 151, no. 3, pp. 367–374, 2004. View at Publisher · View at Google Scholar
  41. Y. Hibi, T. Nagaya, F. Kambe et al., “Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR? fusion mRNA?” Endocrine Journal, vol. 51, no. 3, pp. 361–366, 2004. View at Publisher · View at Google Scholar
  42. M. Sahin, B. L. Allard, M. Yates et al., “PPAR? staining as a surrogate for PAX8/PPAR? fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 1, pp. 463–468, 2005. View at Publisher · View at Google Scholar
  43. M. N. Nikiforova, R. A. Lynch, P. W. Biddinger et al., “RAS point mutations and PAX8-PPAR? rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 5, pp. 2318–2326, 2003. View at Publisher · View at Google Scholar
  44. P. Castro, L. Roque, J. Magalhães, and M. Sobrinho-Simões, “A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARγ translocation,” International Journal of Surgical Pathology, vol. 13, no. 3, pp. 235–238, 2005. View at Publisher · View at Google Scholar
  45. T. Foukakis, A. Y. M. Au, G. Wallin et al., “The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPAR? fusion,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, pp. 1143–1149, 2006. View at Publisher · View at Google Scholar
  46. T. Dwight, S. R. Thoppe, T. Foukakis et al., “Involvement of the PAX8/peroxisome proliferator-activated receptor ? rearrangement in follicular thyroid tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 9, pp. 4440–4445, 2003. View at Publisher · View at Google Scholar
  47. P. Castro, A. P. Rebocho, R. J. Soares et al., “PAX8-PPAR? rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 1, pp. 213–220, 2006. View at Publisher · View at Google Scholar
  48. T. J. Giordano, A. Y. M. Au, R. Kuick et al., “Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation,” Clinical Cancer Research, vol. 12, no. 7, pp. 1983–1993, 2006. View at Publisher · View at Google Scholar
  49. L. Roque, V. M. Nunes, C. Ribeiro, C. Martins, and J. Soares, “Karyotypic characterization of papillary thyroid carcinomas,” Cancer, vol. 92, no. 10, pp. 2529–2538, 2001. View at Publisher · View at Google Scholar
  50. V. B. Wreesmann, R. A. Ghossein, M. Hezel et al., “Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity,” Genes, Chromosomes & Cancer, vol. 40, no. 4, pp. 355–364, 2004. View at Publisher · View at Google Scholar
  51. M. L. Carcangiu, G. Zampi, and A. Pupi, “Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy,” Cancer, vol. 55, no. 4, pp. 805–828, 1985. View at Publisher · View at Google Scholar
  52. P. Castro, E. Fonseca, J. Magalhães, and M. Sobrinho-Simões, “Follicular, papillary, and “hybrid” carcinomas of the thyroid,” Endocrine Pathology, vol. 13, no. 4, pp. 313–320, 2002. View at Publisher · View at Google Scholar
  53. J. G. Powell, X. Wang, B. L. Allard et al., “The PAX8/PPAR? fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPAR? inhibition,” Oncogene, vol. 23, no. 20, pp. 3634–3641, 2004. View at Publisher · View at Google Scholar
  54. A. Y. M. Au, C. McBride, K. G. Wilhelm Jr. et al., “PAX8-peroxisome proliferator-activated receptor ? (PPAR?) disrupts normal PAX8 or PPAR? transcriptional function and stimulates follicular thyroid cell growth,” Endocrinology, vol. 147, no. 1, pp. 367–376, 2006. View at Publisher · View at Google Scholar
  55. C. Espadinha, B. M. Cavaco, and V. Leite, “PAX8PPARγ stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line,” Thyroid, vol. 17, no. 6, pp. 497–509, 2007. View at Publisher · View at Google Scholar
  56. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 16, no. 2, pp. 109–142, 2006. View at Google Scholar
  57. K. S. Gustafson, V. A. LiVolsi, E. E. Furth, T. L. Pasha, M. E. Putt, and Z. W. Baloch, “Peroxisome proliferator-activated receptor γ expression in follicular-patterned thyroid lesions: caveats for the use of immunohistochemical studies,” American Journal of Clinical Pathology, vol. 120, no. 2, pp. 175–181, 2003. View at Publisher · View at Google Scholar
  58. D. Fabbro, C. Di Loreto, C. A. Beltrami, A. Belfiore, R. Di Lauro, and G. Damante, “Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms,” Cancer Research, vol. 54, no. 17, pp. 4744–4749, 1994. View at Google Scholar
  59. J. P. Klopper, W. R. Hays, V. Sharma, M. A. Baumbusch, J. M. Hershman, and B. R. Haugen, “Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment,” Molecular Cancer Therapeutics, vol. 3, no. 8, pp. 1011–1120, 2004. View at Google Scholar
  60. G. D. Demetri, C. D. M. Fletcher, E. Mueller et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-? ligand troglitazone in patients with liposarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999. View at Publisher · View at Google Scholar
  61. E. Mueller, M. Smith, P. Sarraf et al., “Effects of ligand activation of peroxisome proliferator-activated receptor ? in human prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10990–10995, 2000. View at Publisher · View at Google Scholar
  62. F. Grünwald, C. Menzel, H. Bender et al., “Redifferentiation therapy-induced radioiodine uptake in thyroid cancer,” The Journal of Nuclear Medicine, vol. 39, no. 11, pp. 1903–1906, 1998. View at Google Scholar
  63. F. Grunwald, E. Pakos, H. Bender et al., “Redifferentiation therapy with retinoic acid in follicular thyroid cancer,” The Journal of Nuclear Medicine, vol. 39, no. 9, pp. 1555–1558, 1998. View at Google Scholar
  64. D. Simon, J. Koehrle, C. Reiners et al., “Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma,” World Journal of Surgery, vol. 22, no. 6, pp. 569–574, 1998. View at Publisher · View at Google Scholar
  65. Y. Zhang, S. Jia, Y. Liu et al., “A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer,” Nuclear Medicine Communications, vol. 28, no. 4, pp. 251–255, 2007. View at Publisher · View at Google Scholar
  66. D. Simon, C. Körber, M. Krausch et al., “Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study,” European Journal of Nuclear Medicine & Molecular Imaging, vol. 29, no. 6, pp. 775–782, 2002. View at Publisher · View at Google Scholar
  67. S. C. Short, A. Suovuori, G. Cook, G. Vivian, and C. Harmer, “A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer,” Clinical Oncology, vol. 16, no. 8, pp. 569–574, 2004. View at Publisher · View at Google Scholar
  68. J.-C. Philips, C. Petite, J.-P. Willi, F. Buchegger, and C. A. Meier, “Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers,” Nuclear Medicine Communications, vol. 25, no. 12, pp. 1183–1186, 2004. View at Publisher · View at Google Scholar
  69. A. N. Elias and P. Lizotte, “Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone,” Clinical Nuclear Medicine, vol. 31, no. 9, pp. 517–519, 2006. View at Publisher · View at Google Scholar
  70. E. Kebebew, M. Peng, E. Reiff et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” Surgery, vol. 140, no. 6, pp. 960–967, 2006. View at Publisher · View at Google Scholar
  71. J. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPAR? agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006. View at Publisher · View at Google Scholar